Skip to main content
SpringerLink
Log in

Treatment Strategies in Multiple Sclerosis

  • Chapter
  • First Online:
Handbook of Relapsing-Remitting Multiple Sclerosis

Abstract

Multiple sclerosis (MS) is one of the leading causes of disability among young adults and presents a major health burden in the USA and other Western countries. Disease-modifying therapies (DMTs) for MS are primarily aimed at reducing relapse rate and disability accumulation over time, and have been shown to significantly decrease disease activity clinically as well as radiographically on MRI. In the past several years, the number of therapies for this debilitating disease has greatly increased, offering the ability to tailor treatment plans based on severity of disease, personal preference, risk tolerance, and comorbidities. However, new treatments also come with new safety concerns and monitoring requirements with which physicians must familiarize themselves. This chapter will review the data regarding the treatment options currently available. Finally, while the armamentarium of treatment options for relapsing forms of MS has expanded over the past few years, no currently available therapy has been efficacious in the treatment of (primary or secondary) progressive MS without relapses, and emerging treatment strategies are aimed at addressing this issue (see Chap. 5).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. O’Riordan JI, Thompson AJ, Kingsley DP, MacManus DG, Kendall BE, Rudge P, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 1998;121(Pt 3):495–503.

    Article  PubMed  Google Scholar 

  2. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol. 2001;132:463–71.

    Article  Google Scholar 

  3. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8:987–97.

    Article  CAS  PubMed  Google Scholar 

  4. Filippi M, Rovaris M, Inglese M, Barkof F, De Stefano N, Smith S, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:1489–96.

    Article  CAS  PubMed  Google Scholar 

  5. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503–11.

    Article  CAS  PubMed  Google Scholar 

  6. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977–86.

    Article  CAS  PubMed  Google Scholar 

  7. Penner IK, Stemper B, Calabrese P, Freedman MS, Polman CH, Edan G, et al. Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Mult Scler. 2012;18:1466–71.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Avasarala JR. Clinically isolated syndrome – rethinking the diagnosis. J Neurol Sci. 2015;353:79–80.

    Article  PubMed  Google Scholar 

  9. Perez-Rico C, Ayuso-Peralta L, Rubio-Perez L, Roldan-Diaz I, Arevalo-Serrano J, Jimenez-Jurado D, et al. Evaluation of visual structural and functional factors that predict the development of multiple sclerosis in clinically isolated syndrome patients. Invest Ophthalmol Vis Sci. 2014;55:6127–31.

    Article  PubMed  Google Scholar 

  10. Martinelli V, Dalla Costa G, Colombo B, Dalla Libera D, Rubinacci A, Filippi M, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler. 2014;20:147–55.

    Article  CAS  PubMed  Google Scholar 

  11. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology. 2002;58(8 Suppl 4):S3–9.

    Article  CAS  PubMed  Google Scholar 

  12. IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article]. Neurology. 2001;57(12 Suppl 5):S3–9.

    Google Scholar 

  13. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39:285–94.

    Article  CAS  PubMed  Google Scholar 

  14. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352:1498–504.

    Google Scholar 

  15. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, et al. Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13:657–65.

    Article  CAS  PubMed  Google Scholar 

  16. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet. 2002;359:1453–60.

    Article  CAS  PubMed  Google Scholar 

  17. Panitch H, Goodin D, Francis G, Chang P, Coyle P, O’Connor P, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci. 2005;239:67–74.

    Article  CAS  PubMed  Google Scholar 

  18. Limmroth V, Malessa R, Zettl UK, Koehler J, Japp G, Haller P, et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol. 2007;254:67–77.

    Article  CAS  PubMed  Google Scholar 

  19. Patten SB, Francis G, Metz LM, Lopez-Bresnahan M, Chang P, Curtin F. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler. 2005;11:175–81.

    Article  CAS  PubMed  Google Scholar 

  20. Bayer. Betaseron® FDA Prescribing Information. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm087676.pdf. Accessed 29 June 2016.

  21. Pfizer. Rebif® FDA Prescribing Information. www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm106178.pdf. Accessed 29 June 2016.

  22. Biogen. Avonex® FDA Prescribing Information. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm086060.pdf. Accessed 29 June 2016.

  23. Paolicelli D, D’Onghia M, Pellegrini F, Direnzo V, Iaffaldano P, Lavolpe V, et al. The impact of neutralizing antibodies on the risk of disease worsening in interferon beta-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol. 2013;260:1562–8.

    Article  CAS  PubMed  Google Scholar 

  24. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268–76.

    Article  CAS  PubMed  Google Scholar 

  25. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50:701–8.

    Article  CAS  PubMed  Google Scholar 

  26. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging – measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001;49:290–7.

    Article  CAS  PubMed  Google Scholar 

  27. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R. Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol. 2013;73:705–13.

    Article  CAS  PubMed  Google Scholar 

  28. Wolinsky JS, Borresen TE, Dietrich DW, Wynn D, Sidi Y, Steinerman JR, et al. GLACIER: an open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2015;4:370–6.

    Article  PubMed  Google Scholar 

  29. Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology. 2009;72:1976–83.

    Article  CAS  PubMed  Google Scholar 

  30. Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903–14.

    Article  CAS  PubMed  Google Scholar 

  31. O’Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8:889–97.

    Article  PubMed  Google Scholar 

  32. Teva. Copaxone® FDA Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020622s057lbl.pdf.

  33. Onmez A, Eminler AT, Ergenc H, Baykara M, Uslan I, Tamer A. Drug-induced liver injury by glatiramer acetate used for treatment of multiple sclerosis: a case report. J Investig Med High Impact Case Rep. 2013;1:2324709613517493.

    PubMed  PubMed Central  Google Scholar 

  34. Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.

    Article  CAS  PubMed  Google Scholar 

  35. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–23.

    Article  CAS  PubMed  Google Scholar 

  36. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–80.

    Article  CAS  PubMed  Google Scholar 

  37. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68:295–303.

    Article  PubMed  Google Scholar 

  38. Gueguen A, Roux P, Deschamps R, Moulignier A, Bensa C, Savatovsky J, et al. Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85:1038–40.

    Article  PubMed  Google Scholar 

  39. O’Connor PW, Goodman A, Kappos L, Tornes L. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76:1858–65.

    Article  PubMed  Google Scholar 

  40. Novartis. Gilenya Safety Update 2015. http://www.novartis.com/newsroom/product-related-info-center/gilenya-safety-update.shtml, 2015. Accessed 30 June 2016.

  41. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:21453–7.

    Article  CAS  PubMed  Google Scholar 

  42. Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.

    Article  CAS  PubMed  Google Scholar 

  43. Kappos L, O’Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;84:1582–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.

    Article  CAS  PubMed  Google Scholar 

  45. Aguiar C, Batista S, Pacheco R. Cardiovascular effects of fingolimod: relevance, detection and approach. Rev Port Cardiol. 2014;34:279–85.

    Google Scholar 

  46. Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355:1124–40.

    Article  CAS  PubMed  Google Scholar 

  47. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545–56.

    Article  CAS  PubMed  Google Scholar 

  48. Brooks M. Third Case of PML With Fingolimod (Gilenya) in MS. www.medscape.com/viewarticle/849677. Accessed 30 June 2016.

  49. Novartis. Gilenyaâ„¢ (fingolimod) Highlights of Prescribing Information. www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf. Accessed 30 June 2016.

  50. Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2010;124:75–84.

    Article  PubMed  Google Scholar 

  51. Confavreux C, O’Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247–56.

    Article  CAS  PubMed  Google Scholar 

  52. O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–303.

    Article  PubMed  Google Scholar 

  53. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20:705–16.

    Article  CAS  PubMed  Google Scholar 

  54. Genzyme. AUBAGIO® (teriflunomide) Highlights of Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdf, 2015.

  55. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367:1098–107.

    Article  CAS  PubMed  Google Scholar 

  56. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367:1087–97.

    Article  CAS  PubMed  Google Scholar 

  57. Biogen. Tecfidera® FDA Prescribing Information. www.tecfidera.com/pdfs/full-prescribing-info.pdf. Accessed 30 June 2016.

  58. Nieuwkamp DJ, Murk JL, van Oosten BW, Cremers CH, Killestein J, Viveen MC, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med. 2015;372:1474–6.

    Article  CAS  PubMed  Google Scholar 

  59. Genzyme. LEMTRADAâ„¢ (alemtuzumab) Highlights of Prescribing Information. 2015. www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf. Accessed 30 June 2015.

  60. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–39.

    Article  CAS  PubMed  Google Scholar 

  61. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–28.

    Article  CAS  PubMed  Google Scholar 

  62. Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74:1463–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol. 2015;72:152–8.

    Article  PubMed  Google Scholar 

  64. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:525–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, et al. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386:974–81.

    Article  PubMed  Google Scholar 

  66. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76:294–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology. 1989;39:969–71.

    Article  CAS  PubMed  Google Scholar 

  68. Ontaneda D, Rae-Grant AD. Management of acute exacerbations in multiple sclerosis. Ann Indian Acad Neurol. 2009;12:264–72.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Sahraian MA, Yadegari S, Azarpajouh R, Forughipour M. Avascular necrosis of the femoral head in multiple sclerosis: report of five patients. Neurol Sci. 2012;33:1443–6.

    Article  CAS  PubMed  Google Scholar 

  70. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004;127(Pt 6):1353–60.

    Article  PubMed  Google Scholar 

  71. Salminen HJ, Leggett H, Boggild M. Glatiramer acetate exposure in pregnancy: preliminary safety and birth outcomes. J Neurol. 2010;257:2020–3.

    Article  CAS  PubMed  Google Scholar 

  72. Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, et al. Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology. 2010;75:1794–802.

    Article  CAS  PubMed  Google Scholar 

  73. Tsui A, Lee MA. Multiple sclerosis and pregnancy. Curr Opin Obstet Gynecol. 2011;23:435–9.

    Article  PubMed  Google Scholar 

  74. Chitnis T. Pediatric demyelinating diseases. Continuum (Minneap Minn). 2013;19(4 Multiple Sclerosis):1023–45.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Asaff Harel & Ilana Katz-Sand

Authors
  1. Asaff Harel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilana Katz-Sand
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Asaff Harel .

Editor information

Editors and Affiliations

  1. Icahn School of Medicine at Mount Sinai, New York, USA

    Aaron Miller

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Harel, A., Katz-Sand, I. (2017). Treatment Strategies in Multiple Sclerosis. In: Miller, A. (eds) Handbook of Relapsing-Remitting Multiple Sclerosis. Adis, Cham. https://doi.org/10.1007/978-3-319-40628-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-40628-2_4

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-40626-8

  • Online ISBN: 978-3-319-40628-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation